Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Baker

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 2, 2010
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantationDavid A Rizzieri, Robert Storms, Dong-Feng Chen, et al.
Vaccines|March 27, 2019
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell LinePedro M Folegatti, Duncan Bellamy, Amy Flaxman, et al.
The Lancet. Microbe|November 29, 2024
Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UKNicola Borthwick, Natalia Fernandez, Peter J Hayes, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
Ebiomedicine|October 13, 2022
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trialMeera Madhavan, Adam J Ritchie, Jeremy Aboagye, et al.
Science Translational Medicine|September 28, 2018
Prime and target immunization protects against liver-stage malaria in miceAnita Gola, Daniel Silman, Adam A Walters, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Frontiers in Immunology|September 8, 2022
Repeat controlled human malaria infection of healthy UK adults with blood-stage <i>Plasmodium falciparum</i>: Safety and parasite growth dynamicsJo Salkeld, Yrene Themistocleous, Jordan R Barrett, et al.
BMC Immunology|June 28, 2005
Standardization of cytokine flow cytometry assaysHolden T Maecker, Aline Rinfret, Patricia D'Souza, et al.
The Lancet. Microbe|January 13, 2025
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trialsNavin Venkatraman, Alfred B Tiono, Georgina Bowyer, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 2, 2010
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantationDavid A Rizzieri, Robert Storms, Dong-Feng Chen, et al.
Vaccines|March 27, 2019
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell LinePedro M Folegatti, Duncan Bellamy, Amy Flaxman, et al.
The Lancet. Microbe|November 29, 2024
Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UKNicola Borthwick, Natalia Fernandez, Peter J Hayes, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
Ebiomedicine|October 13, 2022
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trialMeera Madhavan, Adam J Ritchie, Jeremy Aboagye, et al.
Science Translational Medicine|September 28, 2018
Prime and target immunization protects against liver-stage malaria in miceAnita Gola, Daniel Silman, Adam A Walters, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Frontiers in Immunology|September 8, 2022
Repeat controlled human malaria infection of healthy UK adults with blood-stage <i>Plasmodium falciparum</i>: Safety and parasite growth dynamicsJo Salkeld, Yrene Themistocleous, Jordan R Barrett, et al.
BMC Immunology|June 28, 2005
Standardization of cytokine flow cytometry assaysHolden T Maecker, Aline Rinfret, Patricia D'Souza, et al.
The Lancet. Microbe|January 13, 2025
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trialsNavin Venkatraman, Alfred B Tiono, Georgina Bowyer, et al.
Pageof 5